Study to Evaluate Pharmacokinetics, Relative Bioavailability, Palatability of Obefazimod Minitablet Formulation
← catalyst calendarNCT07453784 · readout ≤ 42 d
Sponsored by Abivax S.A. (industry) · ABVX — their whole pipeline →. With Quotient Sciences.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
44estimated
Sites
1
Country
United Kingdom
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-03-03 | actual | When the study began enrolling |
| Primary completion | Sep 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Oct 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2026-03-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy
Interventions
- Drug: Obefazimod 50 mg Capsule
- Drug: Obefazimod Minitablet 50 mg
Primary outcomes
what the primary-completion date above is the date OFMaximum Plasma Concentration (Cmax)
measured Up to 336 hours post-dose (Day 15) at each period
Area under the plasma concentration versus time curve from time zero up to the last measurable concentration (AUC (0-last)
measured Up to 336 hours post-dose (Day 15) at each period
Area under the plasma concentration versus time curve up from time zero to infinity [AUC(0-inf)]
measured Up to 336 hours post-dose (Day 15) at each period
Permalink · ABVX's whole pipeline · Catalyst calendar · Every registered study · What changed